{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-020233","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.445246+00:00","generated_at":"2026-06-25T15:23:50.692147+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Graphite Bio presents preclinical GPH102 data for beta-thalassemia; HDR rates up to 40%","bullets":["Preclinical gene replacement data for GPH102 presented at ASGCT; HDR rates up to 40% in sickle cell HSPCs restoring HbA expression.","GPH102 aims to replace mutated beta-globin gene to treat beta-thalassemia, targeting IND submission by mid-2024.","Encore poster for GPH101 Phase 1/2 CEDAR trial for sickle cell disease also presented at ASGCT.","Data accepted for encore presentation at EHA 2022 Hybrid Congress in June."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-020233","json":"https://secwatch.observer/filing/0001564590-22-020233.json","markdown":"https://secwatch.observer/filing/0001564590-22-020233.md","text":"https://secwatch.observer/filing/0001564590-22-020233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000156459022020233/0001564590-22-020233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000156459022020233/grph-8k_20220516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T15:23:50.692147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}